SI-BONE, Inc. (FRA:2K3)
Germany · Delayed Price · Currency is EUR | Market Cap | 673.88M -3.5% |
| Revenue (ttm) | 178.86M +16.8% |
| Net Income | -14.48M |
| EPS | -0.33 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 14.40 |
| Previous Close | 14.10 |
| Day's Range | 14.30 - 14.40 |
| 52-Week Range | 9.65 - 17.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About SI-BONE
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the impla... [Read more]
Financial Performance
In 2025, SI-BONE's revenue was $200.93 million, an increase of 20.19% compared to the previous year's $167.18 million. Losses were -$18.90 million, -38.85% less than in 2024.
Financial numbers in USD Financial StatementsNews
SI-BONE Transcript: Truist Securities MedTech Conference 2026
The company has evolved into a multi-product platform targeting a $3.5B TAM, with strong growth in SI joint, trauma, and pelvic fixation markets. Physician base and sales force expansion, new product launches, and partnerships like Smith+Nephew are expected to drive accelerated growth and improved reimbursement through 2028.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bon...
SI-BONE Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, all of which were approved. No questions were raised, and a quorum was established with nearly 88% of shares represented. Final voting results will be filed on Form 8-K.
SI-Bone management to meet with Needham
Meeting to be held in Boston on June 1 and in New York on June 2 hosted by Needham.
SI-Bone price target lowered to $18 from $22 at TD Cowen
TD Cowen analyst Mathew Blackman lowered the firm’s price target on SI-Bone (SIBN) to $18 from $22 and keeps a Buy rating on the shares. The firm said sales and…
SI-BONE Transcript: Bank of America Global Healthcare Conference 2026
Momentum is driven by innovation, expanding physician adoption, and strategic partnerships, with new products and reimbursement changes expected to accelerate growth and profitability through 2026 and beyond. Gross margins remain strong near 80%, and operating leverage is set to improve.
SI-Bone price target lowered to $18 from $20 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on SI-Bone (SIBN) to $18 from $20 and keeps a Buy rating on the shares. The firm notes that its reduced…
SI-Bone reports Q1 EPS (10c), consensus (19c)
Reports Q1 revenue $52.6M, consensus $51.16M. “The first quarter demonstrated the strength and durability of our platform, with record physician engagement and double-digit growth across all key metri...
SI-Bone raises FY26 revenue view $230M-$233M from $228.5M-$232.5M
Consensus $230.44M. Sees gross margin 79%; positive adjusted EBITDA.
SI-BONE Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% revenue growth, strong operating leverage, and raised full-year guidance. New product launches, a key partnership, and favorable CMS reimbursement changes are expected to accelerate growth, with a breakthrough device launch and expanded sales force supporting future momentum.
SI-BONE Earnings release: Q1 2026
SI-BONE released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
SI-BONE Slides: Q1 2026
SI-BONE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
SI-BONE Quarterly report: Q1 2026
SI-BONE has published its Q1 2026 quarterly earnings report on May 11, 2026.
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement...
SI-BONE Slides: Corporate presentation
SI-BONE has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SANTA CLARA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bo...
SI-BONE Proxy statement: Proxy filing
SI-BONE filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
SI-BONE Proxy statement: Proxy filing
SI-BONE filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bo...
SI-Bone price target lowered to $20 from $24 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on SI-Bone (SIBN) to $20 from $24 and keeps a Buy rating on the shares as part of a broader research…
SI-Bone management to meet with Piper Sandler
Meetings to be held in California March 17-18 hosted by Piper Sandler.
SI-BONE Transcript: TD Cowen 46th Annual Health Care Conference
The company is expanding its portfolio and market reach through physician-driven innovation, strategic partnerships like Smith+Nephew, and a robust pipeline targeting unmet needs in spine and trauma. Strong growth, margin focus, and regular new product launches are expected to drive performance through 2028.
SI-Bone files automatic mixed securities shelf
16:32 EST SI-Bone (SIBN) files automatic mixed securities shelf
SI-Bone price target raised to $22 from $21 at TD Cowen
TD Cowen raised the firm’s price target on SI-Bone (SIBN) to $22 from $21 and keeps a Buy rating on the shares. The firm said the company is set up…
SI-Bone price target raised to $24 from $23 at Truist
Truist raised the firm’s price target on SI-Bone (SIBN) to $24 from $23 and keeps a Buy rating on the shares after its Q4 earnings beat. The company complemented its…